TABLE I.
Summary of growth factor biomaterials and the method of the drug encapsulation and delivery. PDGF, platelet derived growth factor; FGF, fibroblast growth factor; EGF, epidermal growth factor; VEGF, vascular endothelial growth factor; and PRP, platelet rich plasma.
| Growth factor | Delivery system | Method | In vivo wound model | References |
|---|---|---|---|---|
| PDGF | Regranex (sodium carboxymethylcellulose gel) | Mixing | Diabetic patients with non-healing, full thickness diabetic foot ulcers | 23 |
| PDGF | Chitosan gel | Mixing | Rats–streptozotocin induced diabetes (full thickness wound) | 24 |
| PDGF | Collagen-chitosan gel | Mixing | Rats (dorsal wound) | 22 |
| PDGF or FGF | Polyethylene glycol | Mixing | Db/db mice (full thickness wound) | 21 |
| FGF-2 | Heparin-poly(ethylene argininylaspartate digylceride) matrix | Coacervation | Mice (full excisional wound) | 33 |
| FGF | Polyurethane hydrogel | Mixing | Mice and rats (full excisional wound) | 32 |
| EGF or FGF | Hyaluronate-collagen dressing | Mixing, lyophilization | Mice–streptozotocin induced diabetes (full thickness wound) | 26 and 27 |
| EGF | Polyvinyl alcohol-alginate gel | Mixing, cross-linking | Rats–streptozotocin induced diabetes (full thickness wound) | 28 |
| EGF | Pluronic-chitosan gel | Mixing, cross-linking | Mice–streptozotocin induced diabetes (dorsal burn) | 25 |
| EGF | Hyaluronate | Aldehyde-amine conjugation | Rats (full excisional wound) | 30 |
| EGF | Poly-lactic-co-glycolic acid | Electrospinning nanofibers | Db/db mice (full thickness wound) | 31 |
| VEGF DNA | Chitosan scaffolds | Freeze dried chitosan soaked in DNA solution | Rats (full excisional wound) | 35 |
| VEGF | Alginate microspheres | Microencapsulation, ion exchange | Rat (incision in groin) | 36 |
| PRP | Platelet gel | Thrombin and calcium activation | Diabetic patients with non-healing foot ulcers | 44 |